CA3213384A1 - Urolithin for increasing stem cell function - Google Patents

Urolithin for increasing stem cell function Download PDF

Info

Publication number
CA3213384A1
CA3213384A1 CA3213384A CA3213384A CA3213384A1 CA 3213384 A1 CA3213384 A1 CA 3213384A1 CA 3213384 A CA3213384 A CA 3213384A CA 3213384 A CA3213384 A CA 3213384A CA 3213384 A1 CA3213384 A1 CA 3213384A1
Authority
CA
Canada
Prior art keywords
urolithin
cells
population
stem cell
hspcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3213384A
Other languages
English (en)
French (fr)
Inventor
Mukul Girotra
Nicola Vannini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Ludwig Cancer Research
Original Assignee
Societe des Produits Nestle SA
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Ludwig Cancer Research filed Critical Societe des Produits Nestle SA
Publication of CA3213384A1 publication Critical patent/CA3213384A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Primary Cells (AREA)
CA3213384A 2021-05-05 2022-05-02 Urolithin for increasing stem cell function Pending CA3213384A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172290.5 2021-05-05
EP21172290 2021-05-05
PCT/EP2022/061666 WO2022233767A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Publications (1)

Publication Number Publication Date
CA3213384A1 true CA3213384A1 (en) 2022-11-10

Family

ID=75825544

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3213384A Pending CA3213384A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Country Status (8)

Country Link
US (1) US20240228966A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333832A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516187A (cg-RX-API-DMAC7.html)
CN (1) CN117202903A (cg-RX-API-DMAC7.html)
AU (1) AU2022270331A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022224A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213384A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022233767A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CZ297278B6 (cs) 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US20190083457A1 (en) * 2017-09-15 2019-03-21 The Borad Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators for protecting, expanding and increasing the potency of hematopoietic stem cells
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
MX2020011619A (es) * 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.
US20220241240A1 (en) * 2019-01-18 2022-08-04 Societe Des Produits Nestle S.A. Agents and methods for increasing stem cell function

Also Published As

Publication number Publication date
CN117202903A (zh) 2023-12-08
AU2022270331A9 (en) 2023-10-19
JP2024516187A (ja) 2024-04-12
US20240228966A1 (en) 2024-07-11
AU2022270331A1 (en) 2023-10-12
WO2022233767A1 (en) 2022-11-10
EP4333832A1 (en) 2024-03-13
BR112023022224A2 (pt) 2024-02-06

Similar Documents

Publication Publication Date Title
AU2020209429B2 (en) Agents and methods for increasing stem cell function
Brosseau et al. Prebiotic supplementation during pregnancy modifies the gut microbiota and increases metabolites in amniotic fluid, driving a tolerogenic environment in utero
US20240390425A1 (en) Rejuvenated aged hematopoietic stem cells and methods of use
CN106434552A (zh) 新型nkt样细胞亚群及其治疗肿瘤的用途
US20240010981A1 (en) Compositions and methods for increasing stem cell function
US20230365933A1 (en) Compositions and methods for increasing stem cell function
US20240228966A1 (en) Urolithin for increasing stem cell function
JP2020520237A (ja) 移植に適した臍帯細胞画分の選択と使用
WO2020096672A1 (en) Use of lactoferrin for generating myeloid-derived suppressor cells
HK40104930A (en) Urolithin for increasing stem cell function
HK40058827A (en) Agents and methods for increasing stem cell function
JP2010508854A (ja) 幹細胞移植の後の生着を改善するための方法
HK40096626A (en) Compositions and methods for increasing stem cell function
HK40095240A (en) Compositions and methods for increasing stem cell function
Filip et al. Homing of lin−/CD117+ hematopoietic stem cells
THEILER Role of Short Chain Fatty Acids (SCFA) in Allergic Inflammation
Ngu The influence of diet-induced obesity and exercise on bone marrow extracellular vesicles in an irradiated mouse model
Imanirad et al. HIF1α is a regulator of hematopoietic progenitor and stem cell development
Shao et al. transplant rejection by weakening c-myc-dependent glutaminolysis
Chandrinou et al. Publication only EBMT 2006
Gövert A functional characterisation of the Transplant Acceptance-Inducing Cell
McKAY A Cryopreservation Protocol to Retain T Cell Function and Viability for Use in Donor Leukocyte Infusion

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260428

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260428

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260504

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260504

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260504